Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas. Show more

5300 Memorial Drive, Houston, TX, 77007, United States

https://moleculin.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

12.38M

52 Wk Range

$1.79 - $28.60

Previous Close

$2.23

Open

$2.18

Volume

59,669

Day Range

$2.18 - $2.33

Enterprise Value

3.221M

Cash

8.878M

Avg Qtr Burn

-5.366M

Insider Ownership

0.84%

Institutional Own.

3.34%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Annamycin + Ara-C (Cytarabine) Details Acute myeloid leukemia (AML)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
WP1066 Details Cancer, Brain tumor, Solid tumor/s, Glioma	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Annamycin Details Soft Tissue Sarcoma Lung Metastases	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
WP1066 Details Brain tumor, Solid tumor/s, Cancer, Glioblastoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
WP1122 Details Cancer, Glioblastoma, Brain tumor, Solid tumor/s	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Annamycin/Naxtarubicin (Anthracycline Chemotherapy) Details Acute Myeloid Leukemia (AML), Third Line	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Annamycin/Naxtarubicin (Anthracycline Chemotherapy) Details Acute Myeloid Leukemia (AML), Pediatric	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Annamycin/Naxtarubicin (Anthracycline Chemotherapy) Details Pancreatic Cancer, Third Line	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
WP1220 Details Cutaneous T cell lymphoma, Blood cancer, Cancer, T-cell lymphoma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
WP1122 Details COVID-19	Phase 1a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.